Enasidenib

Enasidenib（CAS 1446502-11-9）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

这个物质在各数据库里的编号

数据库记载的用途

• Enasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
• Enasidenib is an orally available small molecule inhibitor of mutant isocitrate dehydrogenase-2 that is used in the therapy of selected cases of acute myelogenous leukemia (AML). Enasidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Isocitrate Dehydrogenase Inhibitors
• Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of enasidenib; however, CYP3A4 is one of many enzymes involved in enasidenib metabolism.
• Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of enasidenib; however, CYP3A4 is one of many enzymes involved in enasidenib metabolism.
• Take at the same time every day.

它在各数据库里的别名

Enasidenib; 1446502-11-9; CC-90007 Free Base; enasidenibum; 3T1SS4E7AG; CHEBI:145374; DTXSID801027942; RefChem:58279; L01XX59; DTXCID401513509; 107-597-8; AG-221; IDHIFA; AG-221 (Enasidenib); Enasidenib [INN]; AG 221

计算机算出的分子描述符

数据库摘要

Enasidenib · CAS 1446502-11-9 · C19H17F6N7O. UNII 3T1SS4E7AG.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。